Skip directly to content

PubMed Heart Transplant

Subscribe to PubMed Heart Transplant feed PubMed Heart Transplant
NCBI: db=pubmed; Term=heart transplant
Updated: 1 hour 34 min ago

Diagnostic and prognostic value of myocardial blood flow quantification as non-invasive indicator of cardiac allograft vasculopathy.

Thu, 12/14/2017 - 13:45

Diagnostic and prognostic value of myocardial blood flow quantification as non-invasive indicator of cardiac allograft vasculopathy.

Eur Heart J. 2017 Dec 08;:

Authors: Bravo PE, Bergmark BA, Vita T, Taqueti VR, Gupta A, Seidelmann S, Christensen TE, Osborne MT, Shah NR, Ghosh N, Hainer J, Bibbo CF, Harrington M, Costantino F, Mehra MR, Dorbala S, Blankstein R, Desai A, Stevenson L, Givertz MM, Di Carli MF

Abstract
Aims: Cardiac allograft vasculopathy (CAV) is a leading cause of death in orthotopic heart transplant (OHT) survivors. Effective non-invasive screening methods are needed. Our aim was to investigate the added diagnostic and prognostic value of myocardial blood flow (MBF) to standard myocardial perfusion imaging (MPI) with positron emission tomography (PET) for CAV detection.
Methods and results: We studied 94 OHT recipients (prognostic cohort), including 66 who underwent invasive coronary angiography and PET within 1 year (diagnostic cohort). The ISHLT classification was used as standard definition for CAV. Positron emission tomography evaluation included semiquantitative MPI, quantitative MBF (mL/min/g), and left ventricular ejection fraction (LVEF). A PET CAV severity score (on a scale of 0-3) was modelled on the ISHLT criteria. Patients were followed for a median of 2.3 years for the occurrence of major adverse events (death, re-transplantation, acute coronary syndrome, and hospitalization for heart failure). Sensitivity, specificity, positive, and negative predictive value of semiquantitative PET perfusion alone for detecting moderate-severe CAV were 83% [52-98], 82% [69-91], 50% [27-73], and 96% [85-99], respectively {receiver operating characteristic (ROC area: 0.82 [0.70-0.95])}. These values improved to 83% [52-98], 93% [82-98], 71% [42-92], and 96% [97-99], respectively, when LVEF and stress MBF were added (ROC area: 0.88 [0.76-0.99]; P = 0.01). There were 20 major adverse events during follow-up. The annualized event rate was 5%, 9%, and 25% in patients with normal, mildly, and moderate-to-severely abnormal PET CAV grading (P < 0.001), respectively.
Conclusion: Multiparametric cardiac PET evaluation including quantification of MBF provides improved detection and gradation of CAV severity over standard myocardial perfusion assessment and is predictive of major adverse events.

PMID: 29236988 [PubMed - as supplied by publisher]

Association of Whole Blood Tacrolimus Concentrations with Kidney Injury in Heart Transplantation Patients.

Thu, 12/14/2017 - 13:45

Association of Whole Blood Tacrolimus Concentrations with Kidney Injury in Heart Transplantation Patients.

Eur J Drug Metab Pharmacokinet. 2017 Dec 13;:

Authors: Sikma MA, Hunault CC, Kirkels JH, Verhaar MC, Kesecioglu J, de Lange DW

Abstract
BACKGROUND AND OBJECTIVES: Acute kidney injury (AKI) is frequently observed after heart transplantation and is associated with morbidity and mortality. However, many confounding factors also contribute to the development of AKI in heart transplants. We hypothesized that supratherapeutic whole-blood tacrolimus trough concentrations are associated with AKI.
METHODS: In a retrospective observational cohort from April 2005 to December 2012, all adult heart transplantation patients were included. AKI was assessed in the first 2 weeks after transplantation as classified by the Kidney Disease Improving Global Outcomes Network (KDIGO). Whole-blood tacrolimus trough concentrations were determined from day 1 to day 14 and at 1, 3, 6 and 12 months post-transplantation. The therapeutic range was 9 to 15 ng/ml in the first 2 months and tapered to 5-8 ng/ml thereafter. The relationship between supratherapeutic tacrolimus trough concentrations and AKI was evaluated. The impact of various potentially confounding factors on tacrolimus concentrations and AKI was considered.
RESULTS: We included 110 patients. AKI occurred in 57% of patients in the first week. Recovery from AKI was seen in 24%. The occurrence of chronic kidney disease (CKD) was 19% at 1 year. Whole-blood tacrolimus trough concentrations were often supratherapeutic and, despite correction for confounding factors, independently associated with AKI (OR 1.66; 95% CI 1.20-2.31).
CONCLUSIONS: Supratherapeutic whole-blood tacrolimus trough concentrations are independently associated with the development of AKI in adult heart transplantation patients. More stringent dosing of tacrolimus early after transplantation may be critical in preserving the kidney function.

PMID: 29236211 [PubMed - as supplied by publisher]

Paroxysmal bradyarrhythmias are frequent among heart transplant recipients with unexplained syncope: a study based on implantable loop recorders.

Thu, 12/14/2017 - 13:45

Paroxysmal bradyarrhythmias are frequent among heart transplant recipients with unexplained syncope: a study based on implantable loop recorders.

Eur J Heart Fail. 2017 Dec 13;:

Authors: Martínez-Paz E, Barge-Caballero E, Álvarez-Roy L, Barge-Caballero G, Couto-Mallón D, Paniagua-Martín MJ, Mosquera-Pérez I, Pérez-Álvarez L, Muñiz J, Cuenca-Castillo JJ, Vázquez-Rodríguez JM, Crespo-Leiro MG

PMID: 29235712 [PubMed - as supplied by publisher]

Reviewing the use of ventricular assist devices in the elderly: where do we stand today?

Thu, 12/14/2017 - 13:45

Reviewing the use of ventricular assist devices in the elderly: where do we stand today?

Expert Rev Cardiovasc Ther. 2017 Dec 13;:

Authors: Nair N, Gongora E

Abstract
INTRODUCTION: Implantation of left ventricular assist devices (LVADS) in older patients appears to be an attractive option in the wake of donor shortage and increasing incidence and prevalence of end stage heart failure. Since the inception of the artificial heart program half a century ago tremendous progress in research and development has led to utilization of more sophisticated devices. VADs have therefore emerged as a successful therapy for extending life with meaningful quality. Areas covered: This review will address the use of LVADS as a bridge to transplantation, destination therapy and comparison of LVAD therapy with alternate list heart transplantation in the elderly population. Expert commentary: Age >70 years is an important aspect when assessing LVAD risk, but other characteristics appear to be better predictors of LVAD survival. Elevated pre-operative creatinine, bilirubin and ischemic etiology predispose to a higher risk of mortality. Creatinine has been shown to be a very powerful predictor in post LVAD survival. Based on the existing literature, the authors suggest an algorithm which could be useful when evaluating patients for LVAD implantation.

PMID: 29235399 [PubMed - as supplied by publisher]

Follow-Up (Measurement) of Corrected QT Interval in Adult Patients before and after Lung Transplantation.

Thu, 12/14/2017 - 13:45
Related Articles

Follow-Up (Measurement) of Corrected QT Interval in Adult Patients before and after Lung Transplantation.

Biomed Res Int. 2017;2017:4519796

Authors: Bandorski D, Hoeltgen R, Becker N, Padberg W, Bogossian H, Wiedenroth C, Arlt M, Hamm C, Seeger W, Ghofrani HA, Hecker M, Gall H, Mayer K

Abstract
Background: Prolongation of the corrected QT (QTc) interval is well known for many drugs, some of which are an integral part of the therapeutic regimen after lung transplantation (LTX). Therefore, we investigated the QTc interval after LTX in the present study.
Patients and Methods: The medical records of patients after LTX were studied for demographic data, indication of LTX, medication, and baseline and follow-up ECGs. The QT interval was corrected for the patient's heart rate using the different formulae of Bazett, Fridericia, Hodges, and Framingham.
Results: Fifty-nine patients were included. The mean age ± SD was 55.6 ± 7.8 years (median 58 years). After LTX, QTc intervals showed no (relevant) changes during follow-up, even though all patients were treated with drugs (in combination) known to bear a risk of prolonged QTc interval and cortisone. The longest QTc intervals were obtained using Bazett's formula.
Conclusion: The QTc interval did not increase under immunosuppressive medication after LTX in our cohort of patients. We speculate that the concurrent use of cortisone may shorten the QT(c) intervals or cancel out drug-induced prolongation of the QTc interval.

PMID: 29234678 [PubMed - in process]

Transit and integration of extracellular mitochondria in human heart cells.

Thu, 12/14/2017 - 13:45
Related Articles

Transit and integration of extracellular mitochondria in human heart cells.

Sci Rep. 2017 Dec 12;7(1):17450

Authors: Cowan DB, Yao R, Thedsanamoorthy JK, Zurakowski D, Del Nido PJ, McCully JD

Abstract
Tissue ischemia adversely affects the function of mitochondria, which results in impairment of oxidative phosphorylation and compromised recovery of the affected organ. The impact of ischemia on mitochondrial function has been extensively studied in the heart because of the morbidity and mortality associated with injury to this organ. As conventional methods to preserve cardiac cell viability and contractile function following ischemia are limited in their efficacy, we developed a unique approach to protect the heart by transplanting respiration-competent mitochondria to the injured region. Our previous animal experiments showed that transplantation of isolated mitochondria to ischemic heart tissue leads to decreases in cell death, increases in energy production, and improvements in contractile function. We also discovered that exogenously-derived mitochondria injected or perfused into ischemic hearts were rapidly internalised by cardiac cells. Here, we used three-dimensional super-resolution microscopy and transmission electron microscopy to determine the intracellular fate of endocytosed exogenous mitochondria in human iPS-derived cardiomyocytes and primary cardiac fibroblasts. We found isolated mitochondria are incorporated into cardiac cells within minutes and then transported to endosomes and lysosomes. The majority of exogenous mitochondria escape from these compartments and fuse with the endogenous mitochondrial network, while some of these organelles are degraded through hydrolysis.

PMID: 29234096 [PubMed - in process]

Heat Failure Phenotypes Induced by Knockdown of DAPIT in Zebrafish: A New Insight into Mechanism of Dilated Cardiomyopathy.

Thu, 12/14/2017 - 13:45
Related Articles

Heat Failure Phenotypes Induced by Knockdown of DAPIT in Zebrafish: A New Insight into Mechanism of Dilated Cardiomyopathy.

Sci Rep. 2017 Dec 12;7(1):17417

Authors: Nagata Y, Yamagishi M, Konno T, Nakanishi C, Asano Y, Ito S, Nakajima Y, Seguchi O, Fujino N, Kawashiri MA, Takashima S, Kitakaze M, Hayashi K

Abstract
The pathogenesis of heart failure associated with dilated cardiomyopathy (DCM) may result in part from adenosine triphosphate (ATP) dysregulation in the myocardium. Under these conditions, diabetes-associated protein in insulin-sensitive tissue (DAPIT), which is encoded by the upregulated during skeletal muscle growth 5 (USMG5) gene, plays a crucial role in energy production by mitochondrial ATP synthase. To determine whether USMG5 is related to the development of heart failure, we performed clinical and experimental studies. Microarray analysis showed that the expression levels of USMG5 were positively correlated with those of natriuretic peptide precursor A in the human failed myocardium. When endogenous z-usmg5 in zebrafish was disrupted using morpholino (MO) oligonucleotides, the pericardial sac and atrial areas were larger and ventricular fractional shortening was reduced compared to in the control MO group. The expression levels of natriuretic peptides were upregulated in the z-usmg5 MO group compared to in controls. Further, microarray analysis revealed that genes in the calcium signalling pathway were downregulated in the z-usmg5 MO group. These results demonstrate that DAPIT plays a crucial role in the development of heart failure associated with DCM and thus may be a therapeutic target for heart failure.

PMID: 29234032 [PubMed - in process]

Large Cardiac-Muscle Patches Engineered from Human Induced-Pluripotent Stem-Cell-Derived Cardiac Cells Improve Recovery from Myocardial Infarction in Swine.

Thu, 12/14/2017 - 13:45
Related Articles

Large Cardiac-Muscle Patches Engineered from Human Induced-Pluripotent Stem-Cell-Derived Cardiac Cells Improve Recovery from Myocardial Infarction in Swine.

Circulation. 2017 Dec 12;:

Authors: Gao L, Gregorich ZR, Zhu W, Mattapally S, Oduk Y, Lou X, Kannappan R, Borovjagin AV, Walcott GP, Pollard AE, Fast VG, Hu X, Lloyd SG, Ge Y, Zhang J

Abstract
Background -Here, we generated human cardiac muscle patches (hCMPs) of clinically relevant dimensions (4 cm × 2 cm × 1.25 mm) by suspending cardiomyocytes, smooth-muscle cells, and endothelial cells that had been differentiated from human induced-pluripotent stem cells (hiPSCs) in a fibrin scaffold and then culturing the construct on a dynamic (rocking) platform. Methods -In vitro assessments of hCMPs suggest maturation in response to dynamic culture stimulation. In vivo assessments were conducted in a porcine model of myocardial infarction (MI). Animal groups included: MI hearts treated with two hCMPs (MI+hCMP, N=13), treated with two cell-free open fibrin patches (MI+OP, n=14), or with neither experimental patches (MI, n=15); a fourth group of animals underwent sham surgery (SHAM, n=8). Cardiac function and infarct size were evaluated by magnetic resonance imaging, arrhythmia incidence by implanted loop recorders, and the engraftment rate by calculation of quantitative PCR measurements of expression of the human Y chromosome. Additional studies examined the myocardial protein expression profile changes and potential mechanisms of action that related with exosomes from the cell patch. Results -The hCMPs began to beat synchronously within 1 day of fabrication, and after 7 days of dynamic culture stimulation, in vitro assessments indicated the mechanisms related to the improvements in electronic mechanical coupling, calcium-handling, and force-generation suggesting a maturation process during the dynamic culture. The engraftment rate was 10.9±1.8% at 4 weeks after the transplantation. The hCMP transplantation was associated with significant improvements in left ventricular (LV) function, infarct size, myocardial wall stress, myocardial hypertrophy, and reduced apoptosis in the peri-scar boarder zone myocardium. hCMP transplantation also reversed some MI-associated changes in sarcomeric regulatory protein phosphorylation. The exosomes released from the hCMP appeared to have cytoprotective properties that improved cardiomyocyte survival. Conclusions -We have fabricated a clinically relevant size of hCMP with trilineage cardiac cells derived from hiPSCs. The hCMP matures in vitro during 7 days of dynamic culture. Transplantation of this type of hCMP results in significantly reduced infarct size and improvements in cardiac function that are associated with reduction in LV wall stress. The hCMP treatment is not associated with significant changes in arrhythmogenicity.

PMID: 29233823 [PubMed - as supplied by publisher]

Anticoagulant-Free Off-Pump Left Ventricular Assist Device Implant.

Thu, 12/14/2017 - 13:45
Related Articles

Anticoagulant-Free Off-Pump Left Ventricular Assist Device Implant.

Ann Thorac Surg. 2018 Jan;105(1):e37-e39

Authors: Ali J, Balasubramanian S, Berman M, Omar YA, Tsui S

Abstract
Implantable left ventricular assist device (LVAD) therapy is an established treatment for advanced heart failure. LVADs are usually implanted using intra-operative anticoagulation with or without cardiopulmonary bypass. We describe an anticoagulant-free off-pump LVAD implant technique to circumvent potential complications associated with conventional approaches. This technique is safe and is probably the least invasive surgical approach for LVAD implantation.

PMID: 29233363 [PubMed - in process]

Hypoplastic left heart in Turner's syndrome: a primary indication for transplant?

Thu, 12/14/2017 - 13:45
Related Articles

Hypoplastic left heart in Turner's syndrome: a primary indication for transplant?

Cardiol Young. 2017 Dec 13;:1-3

Authors: Philip J, Gupta D, Bleiweis MS, Pietra BA, Vyas HV

Abstract
Survival for hypoplastic left heart syndrome patients following the Norwood procedure is 71-90%. Mortality in patients with Turner's syndrome and hypoplastic left heart syndrome after conventional palliation (Norwood operation) has been reported as high as 80%. This questions the approach of traditional staged palliation. Here, we report a patient with hypoplastic left heart syndrome and Turner's syndrome bridged to orthotopic heart transplantation following a hybrid procedure.

PMID: 29233199 [PubMed - as supplied by publisher]

A π-π conjugation-containing soft and conductive injectable polymer hydrogel highly efficiently rebuilds cardiac function after myocardial infarction.

Thu, 12/14/2017 - 13:45
Related Articles

A π-π conjugation-containing soft and conductive injectable polymer hydrogel highly efficiently rebuilds cardiac function after myocardial infarction.

Biomaterials. 2017 Apr;122:63-71

Authors: Bao R, Tan B, Liang S, Zhang N, Wang W, Liu W

Abstract
Previous studies suggested that a stiffer hydrogel system exhibited a better performance to promote heart function after myocardial infarction (MI). However, the nature of myocardium, a tissue that alternately contracts and relaxes with electrical impulses, leads us to hypothesize that a soft and conductive hydrogel may be in favor of mechanical and electrical signals transmission to enhance heart function after MI. In this work, π-π conjugation interaction was first employed to produce a soft injectable hydrogel with conductive property. Melamine with π-π conjugation ring was used as a core to synthesize a multi-armed crosslinker PEGDA700-Melamine (PEG-MEL), which could crosslink with thiol-modified hyaluronic acid (HA-SH) to form an injectable hydrogel rapidly. By incorporating graphene oxide (GO), the injectable PEG-MEL/HA-SH/GO hydrogel exhibited a soft (G' = 25 Pa) and anti-fatigue mechanical property and conductive property (G = 2.84 × 10-4 S/cm). The hydrogel encapsulating adipose tissue-derived stromal cells (ADSCs) was injected into MI area of rats. The significant increase in α-Smooth Muscle Actin (α-SMA) and Connexin 43 (Cx43) expression confirmed that the gel efficiently promoted the transmission of mechanical and electrical signals. Meanwhile, a significant improvement of heart functions, such as distinct increase of ejection fraction (EF), smaller infarction size, less fibrosis area, and higher vessel density, was achieved.

PMID: 28107665 [PubMed - indexed for MEDLINE]

Isolation of Pig Bone Marrow-Derived Mesenchymal Stem Cells.

Thu, 12/14/2017 - 13:45
Related Articles

Isolation of Pig Bone Marrow-Derived Mesenchymal Stem Cells.

Methods Mol Biol. 2016;1416:225-32

Authors: Feyen DA, van den Akker F, Noort W, Chamuleau SA, Doevendans PA, Sluijter JP

Abstract
Large animal models are an important preclinical tool for the evaluation of new interventions and their translation into clinical practice. The pig is a widely used animal model in multiple clinical fields, such as cardiology and orthopedics, and has been at the forefront of testing new therapeutics, including cell-based therapies. In the clinic, mesenchymal stem cells (MSCs) are used autologously, therefore isolated, and administrated into the same patient. For successful clinical translation of autologous approaches, the porcine model needs to test MSC in a similar manner. Since a limited number of MSCs can be isolated directly from the bone marrow, culturing techniques are needed to expand the population in vitro prior to therapeutic application. Here, we describe a protocol specifically tailored for the isolation and propagation of porcine-derived bone marrow MSCs.

PMID: 27236674 [PubMed - indexed for MEDLINE]

Mesenchymal Stem Cells in Kidney Repair.

Thu, 12/14/2017 - 13:45
Related Articles

Mesenchymal Stem Cells in Kidney Repair.

Methods Mol Biol. 2016;1416:89-107

Authors: Morigi M, Rota C, Remuzzi G

Abstract
Every year 13.3 million people suffer acute kidney injury (AKI), which is associated with a high risk of death or development of long-term chronic kidney disease (CKD) in a substantial percentage of patients besides other organ dysfunctions. To date, the mortality rate per year for AKI exceeds 50 % at least in patients requiring early renal replacement therapy and is higher than the mortality for breast and prostate cancer, heart failure and diabetes combined.Until now, no effective treatments able to accelerate renal recovery and improve survival post AKI have been developed. In search of innovative and effective strategies to foster the limited regeneration capacity of the kidney, several studies have evaluated the ability of mesenchymal stem cells (MSCs) of different origin as an attractive therapeutic tool. The results obtained in several models of AKI and CKD document that MSCs have therapeutic potential in repair of renal injury, preserving renal function and structure thus prolonging animal survival through differentiation-independent pathways. In this chapter, we have summarized the mechanisms underlying the regenerative processes triggered by MSC treatment, essentially due to their paracrine activity. The capacity of MSC to migrate to the site of injury and to secrete a pool of growth factors and cytokines with anti-inflammatory, mitogenic, and immunomodulatory effects is described. New modalities of cell-to-cell communication via the release of microvesicles and exosomes by MSCs to injured renal cells will also be discussed. The translation of basic experimental data on MSC biology into effective care is still limited to preliminary phase I clinical trials and further studies are needed to definitively assess the efficacy of MSC-based therapy in humans.

PMID: 27236667 [PubMed - indexed for MEDLINE]

Height at First RRT and Mortality in Children.

Thu, 12/14/2017 - 13:45
Related Articles

Height at First RRT and Mortality in Children.

Clin J Am Soc Nephrol. 2016 May 06;11(5):832-9

Authors: Ku E, Fine RN, Hsu CY, McCulloch C, Glidden DV, Grimes B, Johansen KL

Abstract
BACKGROUND AND OBJECTIVES: Poor linear growth is common in children with CKD and has been associated with higher mortality. However, recent data in adult dialysis patients have suggested a higher risk of death in persons of tall stature. In this study, we aimed to examine the risk of all-cause and cause-specific mortality in children at both extremes of height at the time of first RRT.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Using the US Renal Data System, we performed a retrospective analysis of 13,218 children aged 2-19 years, who received their first RRT (dialysis or transplant) during 1995-2011. We used adjusted Cox models to examine the association between short (<3rd percentile) and tall (>3rd percentile) stature and risk of death, compared with less extreme heights.
RESULTS: Over a median follow-up of 7.1 years, there were 1721 deaths. Risk of death was higher in children with short (hazard ratio, 1.49; 95% confidence interval, 1.33 to 1.66) and tall stature (hazard ratio, 1.32; 95% confidence interval, 1.03 to 1.69) in adjusted analysis. In secondary analyses, there was a statistically significant interaction between height and body mass index categories (P=0.04), such that the association of tall stature with higher mortality was limited to children with elevated body mass index (defined as ≥95th percentile for age and sex). Children with short stature had a higher risk of cardiac- and infection-related death, whereas children with tall stature had a higher risk of cancer-related death.
CONCLUSIONS: Children with short and tall stature are at higher mortality risk, although this association was modified by body mass index at time of first RRT. Studies to further explore the reasons behind the higher risk of mortality in children with extremes of height at the time of first RRT are warranted.

PMID: 26933189 [PubMed - indexed for MEDLINE]

Heart Transplants, Reflections, & Expectations: Sir Magdi Yacoub reviews the history of heart transplantation and discusses expectations.

Wed, 12/13/2017 - 13:45
Related Articles

Heart Transplants, Reflections, & Expectations: Sir Magdi Yacoub reviews the history of heart transplantation and discusses expectations.

Eur Heart J. 2017 Dec 07;38(46):3420-3422

Authors: Yacoub M

PMID: 29232452 [PubMed - in process]

Commemorative Mural in Cape Town: A new mural of African themes was inaugurated at the Faculty of Health Sciences Art Exhibition in Cape Town to celebrate Chris Barnard's epic first human heart transplant 50 years ago.

Wed, 12/13/2017 - 13:45
Related Articles

Commemorative Mural in Cape Town: A new mural of African themes was inaugurated at the Faculty of Health Sciences Art Exhibition in Cape Town to celebrate Chris Barnard's epic first human heart transplant 50 years ago.

Eur Heart J. 2017 Dec 07;38(46):3417-3419

Authors: Tofield A

PMID: 29232451 [PubMed - in process]

Heart Transplantation in Spain: A review of the heart transplant programme in Spain from its beginning in 1984 by Marisa Crespo-Leiro MD.

Wed, 12/13/2017 - 13:45
Related Articles

Heart Transplantation in Spain: A review of the heart transplant programme in Spain from its beginning in 1984 by Marisa Crespo-Leiro MD.

Eur Heart J. 2017 Dec 07;38(46):3414-3416

Authors: Crespo-Leiro MG

PMID: 29232450 [PubMed - in process]

Heart Transplantation in Bad Oeynhausen, Germany: The Heart Transplant program at the Heart and Diabetes Center Bad Oeynhausen, University Hospital, Ruhr - University Bochum University, Germany.

Wed, 12/13/2017 - 13:45
Related Articles

Heart Transplantation in Bad Oeynhausen, Germany: The Heart Transplant program at the Heart and Diabetes Center Bad Oeynhausen, University Hospital, Ruhr - University Bochum University, Germany.

Eur Heart J. 2017 Dec 07;38(46):3411-3413

Authors: Gummert JF

PMID: 29232449 [PubMed - in process]

Vladimir Petrovich Demikhov (1916-1998): A pioneer of transplantation ahead of his time, who lived out the end of his life as an unknown and in poor circumstances.

Wed, 12/13/2017 - 13:45
Related Articles

Vladimir Petrovich Demikhov (1916-1998): A pioneer of transplantation ahead of his time, who lived out the end of his life as an unknown and in poor circumstances.

Eur Heart J. 2017 Dec 07;38(46):3406-3410

Authors: Matskeplishvili S

PMID: 29232448 [PubMed - in process]

Fifty years of heart transplantation: A journey of courage, innovation and persistence, celebrated in Cape Town.

Wed, 12/13/2017 - 13:45
Related Articles

Fifty years of heart transplantation: A journey of courage, innovation and persistence, celebrated in Cape Town.

Eur Heart J. 2017 Dec 07;38(46):3405

Authors: Emmert MY

PMID: 29232447 [PubMed - in process]

Pages